Amgen starts MariTide autoinjector study as pivotal readouts approach
Amgen is racing toward readouts for its GLP-1 program, reaffirming plans for the candidate in its third quarter earnings report…
Category: Amgen
ESMO 2026: Amgen’s Imdelltra slashes death risk by nearly 60% in small cell lung cancer
New Phase 3 data show that Amgen’s Imdelltra, when combined with AstraZeneca’s Imfinzi, lowered the risk of death and extended…